MA41031A - Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie - Google Patents

Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie

Info

Publication number
MA41031A
MA41031A MA041031A MA41031A MA41031A MA 41031 A MA41031 A MA 41031A MA 041031 A MA041031 A MA 041031A MA 41031 A MA41031 A MA 41031A MA 41031 A MA41031 A MA 41031A
Authority
MA
Morocco
Prior art keywords
autophagic
cysteamine
activators
fatty acid
acid conjugates
Prior art date
Application number
MA041031A
Other languages
English (en)
Inventor
Michael R Jirousek
Chi B Vu
Original Assignee
Catabasis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catabasis Pharmaceuticals Inc filed Critical Catabasis Pharmaceuticals Inc
Publication of MA41031A publication Critical patent/MA41031A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA041031A 2014-11-26 2015-11-24 Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie MA41031A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462084754P 2014-11-26 2014-11-26

Publications (1)

Publication Number Publication Date
MA41031A true MA41031A (fr) 2017-10-03

Family

ID=56075027

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041031A MA41031A (fr) 2014-11-26 2015-11-24 Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie

Country Status (14)

Country Link
US (2) US10251845B2 (fr)
EP (1) EP3223818A4 (fr)
JP (1) JP2017535579A (fr)
KR (1) KR20170087926A (fr)
CN (1) CN107205994A (fr)
AU (1) AU2015353492A1 (fr)
BR (1) BR112017010872A2 (fr)
CA (1) CA2968402A1 (fr)
HK (1) HK1243322A1 (fr)
IL (2) IL252456A0 (fr)
MA (1) MA41031A (fr)
MX (1) MX376742B (fr)
RU (1) RU2017121906A (fr)
WO (1) WO2016086103A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
EP2774925B1 (fr) 2005-11-08 2016-12-28 Vertex Pharmaceuticals Incorporated Modulateurs hétérocycliques de transporteurs à cassette liant l'ATP
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7776905B2 (en) 2006-04-07 2010-08-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008141119A2 (fr) 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulateurs de cftr
HUE031913T2 (en) 2007-12-07 2017-08-28 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
PL2231606T3 (pl) 2007-12-07 2013-07-31 Vertex Pharma Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
KR101727762B1 (ko) 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
CN105130948A (zh) 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
MX355183B (es) 2012-01-25 2018-04-09 Vertex Pharma Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
CA2878057A1 (fr) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Compositions pharmaceutiques de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropane-carboxamide et leur administration
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
KR102576006B1 (ko) 2014-11-18 2023-09-06 버텍스 파마슈티칼스 인코포레이티드 고처리량 시험 고성능 액체 크로마토그래피의 수행 방법
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2018144981A1 (fr) * 2017-02-06 2018-08-09 StemBios Technologies, Inc. Utilisation de cellules souches somatiques pour augmenter l'autophagie
US11566044B2 (en) 2017-07-26 2023-01-31 The University Of Queensland Disulfide bond containing compounds and uses thereof
EP3873453A4 (fr) * 2018-10-30 2022-08-03 University of Florida Research Foundation, Incorporated Compositions d'acides aminés et méthodes de traitement de la fibrose kystique
GB2581362A (en) 2019-02-14 2020-08-19 Univ Of Sunderland Chemical synthesis
WO2021061858A1 (fr) * 2019-09-25 2021-04-01 Frontier Medicines Corporation Conjugués d'autophagie ciblée et procédés
US20230099696A1 (en) * 2020-03-11 2023-03-30 Purdue Research Foundation Nano-composite microparticles of polymyxin
WO2022109198A1 (fr) * 2020-11-19 2022-05-27 Birch Therapeutics, Inc. Formulations de cystamine et utilisations de celles-ci
CN115724786B (zh) * 2021-09-01 2024-01-30 四川大学 酰胺烷二硫邻苯二甲酰亚胺类化合物、其制备方法和用途
CN115806514B (zh) * 2022-12-06 2024-06-04 航天材料及工艺研究所 一种基于动态二硫键的无溶剂型自修复聚氨酯及其制备方法
CN120437102B (zh) * 2025-07-09 2025-09-16 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2315740T1 (en) 2008-07-08 2018-03-30 Catabasis Pharmaceuticals, Inc. Fatty acids acetylated salicylates and their uses
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
RU2569063C2 (ru) 2009-09-01 2015-11-20 Катабэйсис Фармасьютикалз, Инк. Конъюгаты жирных кислот и ниацина и их применение
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011044138A1 (fr) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Dérivés de salicylate acylé d'acide lipoïque et leurs utilisations
US20110082120A1 (en) 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
WO2011044136A1 (fr) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Dérivés d'acipimox d'acide gras et leurs utilisations
WO2011044139A1 (fr) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Dérivés d'acifran et d'acides gras et leurs utilisations
WO2011044141A1 (fr) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Dérivés de fibrates et d'acides gras et leurs utilisations
DK2521447T3 (en) 2010-01-08 2017-09-18 Catabasis Pharmaceuticals Inc Fatty Acid Fumarates and Their Uses
US20130190327A1 (en) 2010-02-26 2013-07-25 Catabasis Pharmaceuticals Inc Bis-fatty acid conjugates and their uses
US20110212958A1 (en) 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Fatty acid raloxifene derivatives and their uses
US20110213028A1 (en) 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Fatty acid mycophenolate derivatives and their uses
WO2011109681A1 (fr) 2010-03-05 2011-09-09 Catabasis Pharmaceuticals, Inc. Dérivés d'inhibiteurs de cox d'acide gras et utilisations associées
US20130045939A1 (en) 2010-03-19 2013-02-21 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
WO2012115695A1 (fr) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Conjugués de bis-acides gras et leurs utilisations
WO2012161798A1 (fr) 2011-02-25 2012-11-29 Catabasis Pharmaceuticals, Inc. Conjugués d'acide gras et d'acide gamma-aminobutyrique (gaba) et leurs applications
EP2949344A3 (fr) 2011-03-18 2016-01-13 Catabasis Pharmaceuticals, Inc. Utilisation d'enzymes intracellulaires pour libérer des produits bioactifs liés par covalence
US20120252810A1 (en) 2011-04-04 2012-10-04 Catabasis Pharmaceuticals, Inc. Fatty acid non-flushing niacin derivatives and their uses
EP2701509A4 (fr) 2011-04-29 2015-06-17 Catabasis Pharmaceuticals Inc Dérivés de guanidine d'acide gras et de guanidine de salicylate et leurs utilisations
WO2012154564A1 (fr) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Dérivés phénoliques d'acides gras et leurs utilisations
US9029548B2 (en) 2011-05-06 2015-05-12 Catabasis Pharmaceuticals, Inc. Fatty acid lenalidomide derivatives and their uses
WO2012154554A1 (fr) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Dérivés de triterpène d'acide gras et leurs utilisations
WO2014045293A1 (fr) 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Amides d'acides gras comportant un groupe cystéamine ou un groupe cystéamine acétylé et leurs utilisations
US20130059801A1 (en) * 2011-08-31 2013-03-07 Catabasis Pharmaceuticals, Inc. Fatty acid amides, compositions and methods of use
CA2847418A1 (fr) 2011-08-31 2013-03-07 Catabasis Pharmaceuticals, Inc. Amides d'acide gras utiles dans le traitement des maladies inflammatoires
WO2013090420A2 (fr) 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Conjugués acide gras antivirus et leurs utilisations
KR20150004894A (ko) 2012-05-01 2015-01-13 카타베이시스 파마슈티칼즈, 인코포레이티드 스타틴 및 ｆｘｒ 작용제의 지방산 컨쥬게이트들； 조성물 및 이용 방법
KR20150059638A (ko) 2012-05-25 2015-06-01 카타베이시스 파마슈티칼즈, 인코포레이티드 전구단백질 전환효소 섭틸리신/켁신 9형 저하 방법
CA2896776A1 (fr) 2013-01-07 2014-07-10 Jean E. Bemis Utilisation de conjugues d'acides gras et de niacine en vue du traitement de maladies
US20140288025A1 (en) 2013-03-13 2014-09-25 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
WO2014204856A1 (fr) 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Dérivés d'acides gras anti-cancéreux et leurs utilisations
JP2016537353A (ja) 2013-11-15 2016-12-01 カタバシス ファーマシューティカルズ，インコーポレイテッド 脂肪酸ナイアシン複合体
WO2016086136A1 (fr) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Conjugués de cystéamine d'acide gras de modulateurs de cftr et leur utilisation dans le traitement de troubles médicaux
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
US20170342046A1 (en) 2016-05-24 2017-11-30 Catabasis Pharmaceuticals, Inc. Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders

Also Published As

Publication number Publication date
CA2968402A1 (fr) 2016-06-02
KR20170087926A (ko) 2017-07-31
RU2017121906A3 (fr) 2019-06-03
WO2016086103A1 (fr) 2016-06-02
US10251845B2 (en) 2019-04-09
US20170258741A1 (en) 2017-09-14
EP3223818A1 (fr) 2017-10-04
US20200038342A1 (en) 2020-02-06
RU2017121906A (ru) 2018-12-26
IL275578A (en) 2020-08-31
BR112017010872A2 (pt) 2018-01-09
AU2015353492A1 (en) 2017-06-08
MX376742B (es) 2025-03-07
HK1243322A1 (zh) 2018-07-13
MX2017006702A (es) 2018-01-11
CN107205994A (zh) 2017-09-26
EP3223818A4 (fr) 2018-04-25
JP2017535579A (ja) 2017-11-30
IL252456A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
FR26C1007I1 (fr) 19-nor-c21-n-pyrazolyl-steroides c3,3-disubstitues et procedes d'utilisation de ceux-ci
IL275578A (en) Fatty acid conjugates of cysteamine and their uses as activators of autophagy
IL248519A0 (en) Bioceramic compositions and biomodulatory uses thereof
EP2906258A4 (fr) Compositions permettant de moduler l'expression de c90rf72
EP2912178A4 (fr) Super-activateurs et procédés d'utilisation de ceux-ci
EP3146039A4 (fr) Gelée de wharton micronisée
SI3513806T1 (sl) Sestava imunogena
PL2964250T3 (pl) Peptydy i kompozycje do leczenia uszkodzenia stawu
EP3386986A4 (fr) Conjugués porphyrine d'or-peg et procédés d'utilisation
HRP20182046T1 (hr) Uređaj za kuhanje i postupak njegove upotrebe
LT3292875T (lt) Kompozicijos ir būdai, skirti ligų gydymui
EP2910600A4 (fr) Composition d'ester de cellulose
EP3167049A4 (fr) Gelée de wharton micronisée
HUE046736T2 (hu) Karboxilcsoportot tartalmazó polimer és alkalmazása
IL251379A0 (en) Compositions for oral care containing zinc, arginine and serine
SG11201608217PA (en) Fatty acid composition and use thereof
EP2899580A4 (fr) Objectif d'endoscope
EP2814897A4 (fr) Compositions caloporteuses et procédés s'y rapportant
EP2854822A4 (fr) Compositions de polysaccharide et procédés d'utilisation
EP2981529A4 (fr) Analogues d'oridonine, compositions et procédés associés
EP3149099A4 (fr) Compositions d'acide synthétique et leurs utilisation
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.
EP2837627A4 (fr) Dérivé d'amidopyridine, et son utilisation
EP2889307A4 (fr) Peptide alpha-conotoxine et composition médicale et leur objectif
PL2961822T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie